Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
Publisher DOI
Abstract
The Breast International Group (BIG) 1-98 study is a four-arm trial comparing 5 years of monotherapy with tamoxifen or with letrozole or with sequences of 2 years of one followed by 3 years of the other for postmenopausal women with endocrine-responsive early invasive breast cancer. From 1998 to 2003, BIG -98 enrolled 8,010 women. The enhanced design f the trial enabled two complementary analyses of efficacy and safety. Collection of tumor specimens further enabled treatment comparisons based on tumor biology. Reports of BIG 1-98 should be interpreted in relation to each individual patient as she weighs the costs and benefits of available treatments.
Date Issued
2011
Publication Type
Article
Language(s)
en
Author(s)
Regan, Meredith M. | |
Price, Karen N. | |
Giobbie-Hurder, Anita | |
Thürlimann, Beat | |
Gelber, Richard D. |
Journal
Breast cancer research
Publisher
BioMed Central Ltd.
ISSN
1465-5411
Access(Rights)
restricted